How novel technologies for antibody and nucleic acid therapeutics enable medical progress

Date

May 22, 2014

Time

10:30 AM - 11:30 AM

Speaker

Kruip/Wonerow/Jahn-Hofmann

Affiliation

Sanofi

Language

en

Main Topic

Biologie

Other Topics

Biologie

Host

Ivan Baines

Description

Short profiles: Dr. Jochen Kruip, Department Head Novel Protein Therapeutics Studied Chemistry and Biology at the Universities Münster and Göttingen, finishing 1991 with a Diploma Thesis at the MPI of Experimental Medicine (Prof. HJ Gabius). 1995 PhD thesis at Universities Münster and Bochum on membrane protein structure-function relationships. 1995-1997 Post Doc at the Tokyo Institute of Technology working on membrane proteins involved in energy metabolisms of bacteria. Research group leader at the University of Bochum (1997-2001). Joined Sanofi 2001 with positions of increasing responsibility. Now leading a BioInnovation group with a research interest on the development of innovative protein formats to enable new therapeutic interventions in key disease areas such as Oncology and Diabetes. to realize therapeutic intervention through innovative biotherapeutic molecukles. Dr. Peter Wonerow, Section Head Novel Protein Therapeutics Completed his studies of biology 1995 at the Universities of Leipzig and Halle with diploma in biology). PhD (1999) in Biochemistry at the University of Leipzig Medical Center with a thesis on "Mutations of the Thyroid-stimulating receptor and molecular mechanisms of receptor activation". From 1999 to 2003 Post Doc at the University of Oxford, Department of Pharmacology, in the area of platelet signaling/Thrombosis. Joined Sanofi´s Thrombosis unit in 2003, 2009 transfer to the Biotherapeutics unit working on protein therapeutics in Oncology and Immunology. Current research focus on the further development and use of a proprietary bispecific antibody platform technology primarily in the area of immune cell engagement. cell engaging approaches and beyond. Dr. Kerstin Jahn-Hofmann, Section Head Nucleic Acid Therapeutics Platform Studied Chemistry at the University of Frankfurt (1994-1999) while being co-founder of BioSpring (Service Provider, 1997-1999). Continued in Frankfurt with a PhD (2004) followed by a Post-Doc at the University of Saarland (2004-2006). Joined Roche 2006 before starting 2011 as principal scientist at Sanofi. Since 2013 section leader of Chemistry in the Nucleic Acid Therapeutics Platform. In this role she works and advises project teams on key questions in the development of nucleic acid therapeutics such as delivery options, activity and stability of nucleic acids, PK and PD optimization, toxicity issues, target validation.

Last modified: May 23, 2014, 9:40:14 AM